NCT00113776已完成2 期
A Multicenter, Open-label, Single Arm Clinical Trial to Determine the Safety of ABX-EGF Extended Therapy in Subjects With Metastatic Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Amgen
- 主要终点
- Incidence of Adverse events
研究概览
简要总结
The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in subjects with metastatic colorectal cancer who were previously randomized to best supportive care (BSC) in protocol 20020408 and subsequently determined to have progressive disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject previously randomized to BSC in protocol 20020408 and subsequently determined to have progressive disease - ECOG performance status of 0, 1 or 2 - Adequate hematologic, renal and hepatic function
排除标准
- •Myocardial infarction in time interval between completing 20020408 and enrollment in study - History or evidence of interstitial pneumonitis or pulmonary fibrosis - Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics during the time interval between completing 20020408 protocol and enrollment in this study - Use of systemic chemotherapy or radiotherapy during the time interval between completing 20020408 protocol and enrollment in this study
结局指标
主要结局
Incidence of Adverse events
Changes in Lab values
Incidence of HAHA formation
次要结局
未报告次要终点
研究者
相似试验
终止
1 期
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian CancerRefractory Ovarian Cancer With Recurrent Symptomatic Malignant AscitesNCT02540356Baxalta now part of Shire2
终止
2 期
BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyParoxysmal Nocturnal Hemoglobinuria (PNH)NCT05116774BioCryst Pharmaceuticals12
招募中
不适用
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMRelapsed/Refractory Multiple MyelomaNCT06515262920th Hospital of Joint Logistics Support Force of People's Liberation Army of China10
招募中
2 期
A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of TherapyMultiple MyelomaNCT05998928Wuhan Union Hospital, China10
已完成
2 期
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of UveitisPosterior UveitisPanuveitisUveitisNCT00615693Novartis13